1. Home
  2. Studies
  3. CDT : Clinical Studies (index)
scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.
 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date (Planned) End date

A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines

 		Oncology Phase II Completed 30 September 2004 01 June 2007

Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer

 		Oncology Phase II Completed 08 November 2004 03 November 2007

Cross over comparison of Testosterone serum levels in Hypogonadal men treated with L0074 Testosterone Patch 60 cm2 (2 patches/48H) and oral Testosterone Undecaoate -PANTESTONE® 40mg- (2 caps, bid)

 		Hormonal Phase III Completed 16 March 2005 19 September 2005

Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups

 		Dermatology Phase II Completed 28 April 2005 08 May 2006

Oral Vinorelbine and Cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral Vinorelbine and Cispalatine plus best supportive care or best supportive care alone in stage III Non Small Cell Lung Cancer (NSCLC): randomized Phase III study

 		Oncology Phase III Early termination 02 May 2005 09 May 2012
6 - 10 over 126

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

Phase III  -  COLUMBUS

SPONSOR: PFIZER

Breast cancer 

Phase III    -    EXTENET

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

Phase III - BEACON CRC

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

Phase III     -       ALLELE

SPONSOR: ATARA

 

 

 

 

Studies status

Lorem ipsum dolor

Sed hendrerit lorem augue, at molestie ligula dapibus id. Phasellus eu ullamcorper diam.

Lorem ipsum dolor

Sed at augue ut ex tempor congue convallis sed orci. Suspendisse congue pellentesque velit non convallis. Integer nec risus eu urna finibus ornare nec nec eros.

Lorem ipsum dolor

Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Nulla dapibus id dolor placerat gravida.

Lorem ipsum dolor

Integer vel tortor sapien. Nulla elit tellus, interdum vitae lobortis id, scelerisque nec elit. Donec ut maximus nibh. Nunc sit amet nibh nec leo scelerisque tempus id sed nisi. Duis vehicula sem sit amet elit cursus, nec ultrices turpis cursus.

Lorem ipsum dolor

Donec eget ultrices justo. Donec posuere, nibh quis dignissim feugiat, ante turpis pharetra sapien, vel faucibus magna leo eu quam. Fusce sed massa sapien.

Lorem ipsum dolor

Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Nulla dapibus id dolor placerat gravida.

Lorem ipsum dolor

Nunc congue diam metus, id hendrerit nulla fringilla non. Nullam non interdum dui. Phasellus quis dapibus erat. Aliquam metus ipsum, luctus nec mollis vitae, varius ut massa.